# Single‐cell analysis reveals cytotoxic and memory CD8+ T cells associated with prolonged survival in relapsed/refractory leukaemia patients after haplo+cord haematopoietic stem cell transplantation

**Authors:** Hua Li, Zheyang Zhang, Ming Zhu, Xiaofan Li, Jinxian Dai, Ping Chen, Fei Chen, Xianling Chen, Yiding Yang, Xiaohong Yuan, Ronghan Tang, Zhijuan Zhu, Hongli Lin, Ting Lin, Mengsha Tong, Tao Chen, Yuanzhong Chen, Jialiang Huang, Nainong Li

PMC · DOI: 10.1002/ctm2.70529 · 2026-02-04

## TL;DR

This study shows that a specific type of CD8+ T cell, with both cytotoxic and memory properties, is linked to better survival in leukemia patients after a combined stem cell transplant.

## Contribution

The study identifies a novel CD8+ T cell subtype associated with improved survival in leukemia patients following haplo+cord HSCT.

## Key findings

- CD8+ T cells with cytotoxic and memory properties are enriched in patients receiving haplo+cord HSCT and correlate with prolonged survival.
- Single-cell multi-omics analysis reveals that cytotoxic-related genes in CD8+ T cells are regulated by cooperative enhancer networks.
- Haplo+cord HSCT leads to superior survival outcomes compared to single cord HSCT in relapsed/refractory leukemia patients.

## Abstract

Allogeneic haematopoietic stem cell transplantation (allo‐HSCT) is a curative treatment for haematological malignancies. Sequential transplantation of haploidentical stem cell and umbilical cord blood (haplo+cord HSCT) among recipients with relapsed/refractory (R/R) leukaemia exhibited superior survival outcomes compared with single cord HSCT. However, the underlying mechanisms remain unclear.

Here, we profiled and compared single‐cell gene expression and chromatin accessibility in bone marrow from 16 patients receiving haplo+cord or single cord HSCT.

We observed distinct compositions and functions of global immune landscapes, with haplo+cord HSCT exhibiting effective anti‐tumour and anti‐viral immunity mediated by type I interferon signalling. Analysis of T cells revealed specific CD8+ T cell subtype (CD8‐c1), enriched in recipients with haplo+cord HSCT, which was also confirmed by flow cytometry. Functionally, gene signature scoring suggests a dual effector and memory property of CD8‐c1 that potentially offers long‐term protection. Furthermore, single‐cell multi‐omics analysis delineated the expression of cytotoxic‐related genes up‐regulated in CD8‐c1 are cooperatively regulated by enhancer networks. Notably, a proportion‐based survival analysis indicated that high proportion of CD8‐c1 was associated with better survival.

Our results collectively demonstrate that a population of CD8+ T cells with effector and memory properties contributes to improved survival in patients with R/R leukaemia receiving haplo+cord HSCT.

1. Haplo+cord HSCT yields superior survival compared with single cord HSCT in patients with R/R leukaemia.

2. Single‐cell RNA‐seq revealed a functionally critical CD8⁺ T cell population, with cytotoxic and memory phenotypes, which expands after haplo+cord HSCT and tracks with prolonged survival.

3. Multi‐omics profiling at single‐cell resolution showed that the CD8⁺ T cell elevated cytotoxic‐related genes is orchestrated by a cooperative enhancer network.

## Linked entities

- **Diseases:** leukaemia (MONDO:0004355)

## Full-text entities

- **Genes:** IL3RA (interleukin 3 receptor subunit alpha) [NCBI Gene 3563] {aka CD123, IL-3R-alpha, IL3R, IL3RAY, IL3RX, IL3RY}, Gzmm (granzyme M (lymphocyte met-ase 1)) [NCBI Gene 16904] {aka Lmet1, MMET-1}, IRF4 (interferon regulatory factor 4) [NCBI Gene 3662] {aka IMD131, LSIRF, MUM1, NF-EM5, SHEP8}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, TIGIT (T cell immunoreceptor with Ig and ITIM domains) [NCBI Gene 201633] {aka VSIG9, VSTM3, WUCAM}, GNLY (granulysin) [NCBI Gene 10578] {aka D2S69E, LAG-2, LAG2, NKG5, TLA519}, HAVCR2 (hepatitis A virus cellular receptor 2) [NCBI Gene 84868] {aka CD366, HAVcr-2, KIM-3, SPTCL, TIM3, TIMD-3}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, MAFB (MAF bZIP transcription factor B) [NCBI Gene 9935] {aka DURS3, KRML, MCTO}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, TBX21 (T-box transcription factor 21) [NCBI Gene 30009] {aka IMD88, T-PET, T-bet, TBET, TBLYM}, IKZF2 (IKAROS family zinc finger 2) [NCBI Gene 22807] {aka ANF1A2, HELIOS, ICHAD, IMDIA, ZNF1A2, ZNFN1A2}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, Gzma (granzyme A) [NCBI Gene 14938] {aka Ctla-3, Ctla3, Hf, Hf1, SE1, TSP-1}, CD1C (CD1c molecule) [NCBI Gene 911] {aka BDCA1, CD1, R7}, CTCF (CCCTC-binding factor) [NCBI Gene 10664] {aka CFAP108, FAP108, MRD21}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, KLRF1 (killer cell lectin like receptor F1) [NCBI Gene 51348] {aka CLEC5C, NKp80}, Ctcf (CCCTC-binding factor) [NCBI Gene 13018], EBF1 (EBF transcription factor 1) [NCBI Gene 1879] {aka COE1, EBF, O/E-1, OLF1}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, CX3CR1 (C-X3-C motif chemokine receptor 1) [NCBI Gene 1524] {aka CCRL1, CMKBRL1, CMKDR1, GPR13, GPRV28, V28}, LAG3 (lymphocyte activating 3) [NCBI Gene 3902] {aka CD223}, MX1 (MX dynamin like GTPase 1) [NCBI Gene 4599] {aka IFI-78K, IFI78, MX, MxA, lncMX1-215}, PPBP (pro-platelet basic protein) [NCBI Gene 5473] {aka B-TG1, Beta-TG, CTAP-III, CTAP3, CTAPIII, CXCL7}, PRF1 (perforin 1) [NCBI Gene 5551] {aka HPLH2, P1, PFP}, Tbx21 (T-box 21) [NCBI Gene 57765] {aka TBT1, Tbet, Tblym}, Ets1 (Ets proto-oncogene 1, transcription factor) [NCBI Gene 23871] {aka D230050P06, Ets-1, Tpl1, p54, vs}, PF4 (platelet factor 4) [NCBI Gene 5196] {aka CXCL4, PF-4, SCYB4}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD34 (CD34 molecule) [NCBI Gene 947], HBB (hemoglobin subunit beta) [NCBI Gene 3043] {aka CD113t-C, ECYT6, beta-globin}, RUNX1 (RUNX family transcription factor 1) [NCBI Gene 861] {aka AML1, AML1-EVI-1, AMLCR1, CBF2alpha, CBFA2, EVI-1}, CCR7 (C-C motif chemokine receptor 7) [NCBI Gene 1236] {aka BLR2, CC-CKR-7, CCR-7, CD197, CDw197, CMKBR7}, Gzmk (granzyme K) [NCBI Gene 14945], IRF9 (interferon regulatory factor 9) [NCBI Gene 10379] {aka IRF-9, ISGF3, ISGF3G, p48}, Prf1 (perforin 1 (pore forming protein)) [NCBI Gene 18646] {aka Pfn, Pfp, Prf-1}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, MPO (myeloperoxidase) [NCBI Gene 4353], CD3D (CD3 delta subunit of T-cell receptor complex) [NCBI Gene 915] {aka CD3-DELTA, CD3DELTA, IMD19, T3D}, CEBPB (CCAAT enhancer binding protein beta) [NCBI Gene 1051] {aka C/EBP-beta, IL6DBP, NF-IL6, TCF5}, Gzmb (granzyme B) [NCBI Gene 14939] {aka CCP-1/C11, CCP1, Ctla-1, Ctla1, GZB}, RAD21 (RAD21 cohesin complex component) [NCBI Gene 5885] {aka CDLS4, HR21, HRAD21, MCD1, MGS, NXP1}, Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 12767] {aka CD184, CXC-R4, CXCR-4, Cmkar4, LESTR, PB-CKR}, IGLL1 (immunoglobulin lambda like polypeptide 1) [NCBI Gene 3543] {aka 14.1, AGM2, CD179b, IGL1, IGL5, IGLJ14.1}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, HBD (hypophosphatemic bone disease) [NCBI Gene 100187828], PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, Ltb (lymphotoxin B) [NCBI Gene 16994] {aka LTbeta, Tnfc, Tnfsf3, Tnlg1c, p33}, LEF1 (lymphoid enhancer binding factor 1) [NCBI Gene 51176] {aka ECTD1, ECTD17, LEF-1, TCF10, TCF1ALPHA, TCF7L3}, Nkg7 (natural killer cell group 7 sequence) [NCBI Gene 72310] {aka 2500004F03Rik}, NAMPT (nicotinamide phosphoribosyltransferase) [NCBI Gene 10135] {aka 1110035O14Rik, PBEF, PBEF1, VF, VISFATIN}, Cx3cr1 (C-X3-C motif chemokine receptor 1) [NCBI Gene 13051] {aka mCX3CR1}, SELL (selectin L) [NCBI Gene 6402] {aka CD62L, LAM1, LECAM1, LEU8, LNHR, LSEL}, TCF7 (transcription factor 7) [NCBI Gene 6932] {aka TCF-1}, GATA1 (GATA binding protein 1) [NCBI Gene 2623] {aka CNSHA9, ERYF1, GATA-1, GF-1, GF1, HAEADA}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, IFI44 (interferon induced protein 44) [NCBI Gene 10561] {aka MTAP44, TLDC5, p44}
- **Diseases:** chronic lymphocytic leukaemia (MESH:D015461), acute leukaemia (MESH:D054218), GVHD (MESH:D006086), infection (MESH:D007239), cytotoxic (MESH:D064420), bladder haemorrhage (MESH:D006470), seizures (MESH:D012640), Cancer (MESH:D009369), death (MESH:D003643), R/R leukaemia (MESH:D015458), viral infections (MESH:D014777), chronic (MESH:D002908), (R/R) (MESH:D000069279), central nervous system leukaemia (MESH:D002493), bone marrow disease (MESH:D001855), CLL (MESH:D015451), acute lymphocytic choriomeningitis virus infection (MESH:D054198)
- **Chemicals:** tacrolimus (MESH:D016559), Cy (MESH:D003520), MMF (MESH:D009173), cytarabine (MESH:D003561), MCCNU (MESH:D012673), chromium (MESH:D002857), fludarabine (MESH:C024352), HCST (-), Bu (MESH:D002066), CsA (MESH:D016572), mesna (MESH:D015080), phenytoin sodium (MESH:D010672), Trypan blue (MESH:D014343), PBS (MESH:D007854)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** C) of 43, rs7603438, rs12151621, rs7577293, C1 and C2 in T
- **Cell lines:** GM12878 — Homo sapiens (Human), Transformed cell line (CVCL_7526)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12872979/full.md

---
Source: https://tomesphere.com/paper/PMC12872979